Czech/SlovakiaCzech RepublicSlovakia

Lonza Biotec plant reworked to produce enzymes for ALTU-135

22.11.2007

Kourim/Basel – Lonza Biotec s.r.o. (Kourim, Czech Republic), a specialist for microbial fermentation and manufacturing services, has completed the extension of its production plant in Kourim designed for the cGMP-compliant production of pharmaceutical enzymes for Altus Pharmaceuticals (Cambridge, US). The enzymes are used to treat cystic fibrosis patients with pancreatic insufficiency. The plant will host the production of Altus’ Phase III enzyme replacement product ALTU-135, consisting of the lipase, protease and amylase.
At the end of 2006, Altus charged Lonza with the production of ALTU-135, an orally administered formulation of the three enzymes. To start production in its FDA registered facility in Kourim, Lonza Bio­tec invested a45 million, one third of which came from state coffers, to beef up its downstream processing capabilities for filtration, large scale chromatography, lyophilization and spraydrying. At the same time, the Czech company established a technology transfer program with the technology owners, adding more than 25 new jobs in manufacturing and R & D to the site, which was acquired in 1992 from the former state-owned firm Spofa Kourim. Stefan Borgas, CEO of Lonza Group said: “Lonza is pleased at having completed the complex and challenging technical transformation seamlessly and within the agreed time frame. The collaboration with Altus is a very positive experience, and we are looking forward to our long-term partnership. We are excited to offer this new high-end capability to our growing number of global biopharmaceutical customers. Lonza Kourim is now the leading technology and manufacturing service provider for bio­pharmaceuticals in Eastern Europe.“

Czech/SlovakiaCzech RepublicSlovakia

01.02.2010

Prague – After increasing its investment in mid-January, full-service provider CRO FGK Clinical Research GmbH has become a major shareholder in the Czech contract research organization Avemedica s.r.o. Financial details were not...

Czech/SlovakiaCzech RepublicSlovakia

01.02.2010

Pilzen – German antibody drug development and discovery firm Affimed Therapeutics AG (Heidelberg) has spun-out all of its antibody discovery activities into a new Czech subsidiary – AbCheck s.r.o., which is located in Pilzen....

Czech/SlovakiaCzech RepublicSlovakia

18.09.2009

Prague/Jena – German and Czech researchers under Ales Svatos have opened the door to major improvements in the application of high-throughput metabolomics and systematic analyses of small molecules via MALDI-mass spectrometry...

Czech/SlovakiaCzech RepublicSlovakia

19.07.2009

Ceské Budejovice - The scientists from the Biology Centre of the Czech Academy of Science who coordinated the EU project MOBITAG have tabled a report on their attitudes towards political interference in the EU’s GMO authorisation...

Czech/SlovakiaCzech RepublicSlovakia

14.07.2009

Bratislava – According to a new study released by PG Economics, Slovak farmers would benefit more than counterparts in other EU countries from planting genetically-engineered Bt maize. Regional factors, as well as reducing an...

Czech/SlovakiaCzech RepublicSlovakia

14.07.2009

Vestec – The Czech Academy of Sciences and Charles University plan to build a modern biotechnology and biomedicine center, according to reports issued by the Czech Information Agency. With about 40,000 square meters of floor...

Czech/SlovakiaCzech RepublicSlovakia

13.07.2009

Olomouc – A new cluster with a focus on drug development and diagnostics has been established near Palacky University in Olmouc. Called MedChemBio, the centre seeks to attract companies with an interest in medicinal and...

Czech/SlovakiaCzech RepublicSlovakia

12.07.2009

Prague – A biotech company and a pharmaceutical enterprise are the winners of this year’s “Investor of the Year” competition, which is organised by CzechInvest and the country’s Association for Foreign Investment. At the end of...

Czech/SlovakiaCzech RepublicSlovakia

29.04.2009

Prague – A2Z Bio, the Czech subsidiary of UK-based Yorkshire Bioscience, is investing EUR100,000 at the CKD Prague Technological Innovation Centre to launch production of research reagents and services for the biotech R&D market....

Displaying results 11 to 20 out of 70

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/1/article/lonza-biotec-plant-reworked-to-produce-enzymes-for-altu-135.html

Events

All Events

Stock list

All quotes

TOP

  • BIOFRONTERA2.44 EUR10.91%
  • WILEX2.19 EUR4.29%
  • PAION3.28 EUR1.86%

FLOP

  • SANTHERA83.00 CHF-4.54%
  • EVOLVA1.19 CHF-4.03%
  • BB BIOTECH149.65 EUR-2.95%

TOP

  • PAION3.28 EUR36.1%
  • CO.DON3.05 EUR24.0%
  • FORMYCON8.17 EUR15.9%

FLOP

  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.05 EUR-18.0%
  • 4SC1.01 EUR-14.4%

TOP

  • SANTHERA83.00 CHF2044.7%
  • PAION3.28 EUR245.3%
  • CO.DON3.05 EUR214.4%

FLOP

  • CYTOS0.18 CHF-95.3%
  • 4SC1.01 EUR-46.0%
  • MOLOGEN6.64 EUR-44.2%

No liability assumed, Date: 01.10.2014


Current issue

All issues

Product of the week

Products